Top 3 Picks
2026 Outlook
The Lab Instruments sector is expected to experience robust growth through 2026, propelled by trends such as automation, AI integration in lab equipment, and heightened demand for genomics and personalized medicine tools. With global R&D spending projected to rise by 5-7% annually, the sector could see market expansion to over $50 billion by 2026, supported by recovery in supply chains and emerging applications in environmental testing and drug development. However, potential challenges like regulatory hurdles and economic volatility may temper short-term gains, making selective investments key.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Agilent Technologies Inc.
|
60.8 | $137.95 | $39.3B |
|
2
|
Avantor, Inc.
|
60.2 | $11.46 | $9.3B |
|
3
|
Bruker Corporation
|
59.2 | $48.11 | $5.3B |
|
4
|
Revvity, Inc.
|
59.2 | $98.15 | $10.7B |
|
5
|
10x Genomics, Inc. Class A Common Stock
|
58.8 | $16.62 | $1.5B |
|
6
|
EyePoint Pharmaceuticals, Inc. Common Stock
|
58.2 | $17.48 | $890M |
|
7
|
Seer, Inc. Class A Common Stock
|
58.0 | $1.82 | $124M |
|
8
|
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
|
56.6 | $369.53 | -- |
|
9
|
Waters Corp
|
56.6 | $381.96 | $19.0B |
|
10
|
Bio-Rad Laboratories, Inc.Class A
|
56.3 | $305.27 | $8.1B |
|
11
|
Mettler-Toledo International
|
56.1 | $1411.39 | $26.6B |
|
12
|
Nautilus Biotechnolgy, Inc. Common Stock
|
55.5 | $1.91 | $105M |
|
13
|
Quanterix Corporation Common Stock
|
54.9 | $6.43 | $257M |
|
14
|
Cytek Biosciences, Inc. Common Stock
|
54.8 | $4.92 | $459M |
|
15
|
Harvard Bioscience Inc
|
54.6 | $0.65 | $20M |
In-Depth Analysis: Top Lab Instruments Stocks
A
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its …
Agilent Technologies is a key innovator in the Lab Instruments sector, providing essential measurement technologies for life sciences, diagnostics, and applied tools that support critical research and healthcare advancements. Its broad customer base and three operating segments, including life science tools and consumables, position it as a leader in driving industry progress since its spin-off from Hewlett-Packard in 1999.
Agilent exhibits strong profitability with an 18.8% profit margin and a 20.6% ROE, indicating efficient cost management and effective use of shareholder equity to generate returns. The company's 9.4% revenue growth further supports its financial health, though its 30.1 P/E ratio reflects a premium valuation that assumes continued earnings expansion.
Agilent's 9.4% revenue growth and strong profitability metrics, including an 18.8% profit margin and 20.6% ROE, suggest it is poised for sustained earnings in the expanding life sciences market by 2026. As a sector leader, the company can leverage its innovative tools and diagnostics to capture increasing demand from healthcare and research sectors. Additionally, with a Tradestie Score of 60.8, Agilent offers a balanced opportunity for investors seeking growth in lab instruments, potentially leading to stock appreciation through operational efficiencies and market expansion.
AVTR
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include …
Avantor Inc. is a pivotal player in the Lab Instruments sector, providing essential products and services to high-growth industries like biopharma, healthcare, and advanced technologies, which drive global scientific innovation. Its three geographic segments—Americas, Europe, and AMEA—enable broad market reach, supporting critical applications in research, education, and government sectors.
Avantor's negative profit margin of -1.2% and ROE of -1.5% indicate current unprofitability and inefficient equity utilization, reflecting potential operational challenges in a competitive sector. Additionally, the -5.3% revenue growth highlights declining sales, which could stem from macroeconomic pressures or market saturation, despite a moderate Tradestie Score of 60.2 suggesting some underlying stability.
By 2026, Avantor's strong positioning in expanding biopharma and healthcare markets could drive recovery, as global R&D investments are projected to grow, potentially reversing the -5.3% revenue decline. The company's diverse product offerings and geographic segments may capitalize on innovations in lab instruments, enhancing long-term growth prospects. With a Tradestie Score of 60.2 indicating moderate appeal, investors could benefit from a rebound in demand for essential scientific supplies as economic conditions improve.
BRKR
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Bruker Corporation is a pivotal player in the Lab Instruments sector, providing essential scientific instruments and diagnostic tests that support critical research in life sciences, pharmaceuticals, and biotechnology industries. Its specialized segments, such as BSI BioSpin and BSI Nano, enable advanced analytical capabilities, making it a key supplier for innovation in applied markets and high-tech applications.
Bruker's negative profit margin of -0.6% and ROE of -1.1% highlight current challenges in generating profits and efficiently utilizing equity, indicating potential financial strain in the short term. Despite a slight revenue decline of -0.5%, the Tradestie Score of 59.2/100 suggests moderate overall investment viability, possibly driven by sector-specific opportunities.
By 2026, Bruker's focus on high-growth segments like biotechnology and nanotechnology could drive recovery, as global R&D investments in life sciences are projected to increase, potentially boosting demand for their instruments. The company's diverse portfolio, including BSI CALID for advanced diagnostics, positions it to capitalize on emerging trends in pharmaceutical development and personalized medicine. Additionally, with a Tradestie Score of 59.2/100 indicating room for upside, investors may benefit from operational improvements and market expansion efforts.
RVTY
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening …
Revvity stands out in the Lab Instruments sector by providing essential instruments, tests, services, and software solutions that support key industries like pharmaceutical, biomedical, and environmental markets, enabling advancements in diagnostics and research. Its diagnostics segment, which includes immunodiagnostics, reproductive health, and applied genomics, positions the company as a vital contributor to healthcare innovation and global scientific progress.
Revvity's profit margin of 8.4% reflects moderate profitability in a competitive sector, while its ROE of 3.0% indicates suboptimal returns on equity, suggesting potential inefficiencies in capital utilization. Despite revenue growth of only 2.2%, the high P/E ratio of 50.2 signals market optimism for future earnings potential, though current financial health appears constrained.
By 2026, Revvity's focus on high-demand areas like applied genomics and immunodiagnostics could capitalize on the expanding personalized medicine market, potentially driving revenue growth above the current 2.2% as global healthcare investments rise. The company's diversified segments in pharmaceutical and biomedical fields provide resilience and opportunities for margin improvement, especially with emerging technologies enhancing its product offerings. Additionally, the Tradestie Score of 59.2 suggests moderate upside potential, making it an attractive buy for investors anticipating sector recovery and innovation-driven gains.
TXG
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and …
10x Genomics matters in the Lab Instruments sector as a leader in single-cell and spatial genomics technologies, providing integrated instruments, consumables, and software that enable advanced biological analysis for research and healthcare applications. Its innovative solutions drive discoveries in fields like oncology and neurology, positioning it as a key enabler of precision medicine amid growing demand for high-resolution genomic tools.
10x Genomics exhibits weak profitability with a -11.9% profit margin and -10.1% ROE, indicating challenges in generating earnings from operations and efficiently utilizing shareholder equity. Despite a -1.7% revenue growth rate, the 58.8 Tradestie Score suggests moderate financial stability, potentially allowing for future improvements if cost management and market expansion efforts succeed.
By 2026, investors should consider TXG due to the projected expansion of the genomics market, driven by increasing adoption of personalized medicine and biotechnology innovations, which could reverse the -1.7% revenue decline and boost demand for 10x Genomics' specialized instruments. The company's strong product portfolio, including advanced consumables and software, positions it to capture market share as global R&D spending rises. Additionally, with a 58.8 Tradestie Score, TXG has potential for valuation upside if it achieves operational efficiencies and leverages emerging trends like CRISPR and multi-omics research.
EYPT
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other …
EyePoint Pharmaceuticals matters in the broader healthcare sector, particularly for its specialized role in developing FDA-approved sustained-release treatments for eye diseases, which could integrate with lab instruments for advanced ophthalmic research and diagnostics. Its pre-clinical programs focused on innovative therapies position it as a key player in enhancing treatment precision in ophthalmology, indirectly supporting lab instrument applications in medical research.
EyePoint's ROE of -98.2% reflects severe inefficiencies in profit generation from equity, indicating significant financial strain and potential over-reliance on external funding. The -90.8% revenue growth highlights a sharp decline in sales, underscoring operational challenges that could jeopardize long-term financial health without strategic improvements.
By 2026, EyePoint's FDA-approved ophthalmic products and advancing pre-clinical programs could lead to breakthroughs in eye disease treatments, potentially driving revenue recovery from the current -90.8% growth. The Tradestie Score of 58.2 suggests moderate investment appeal, with opportunities for high returns if their pipeline succeeds in expanding market share. Investors should consider the stock for its potential in the growing ophthalmology market, where successful developments could yield substantial upside amid increasing demand for sustained-release therapies.
SEER
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Seer Inc. matters in the Lab Instruments sector due to its innovative Proteograph Product Suite, which leverages proprietary engineered nanoparticle technology to deliver unbiased proteomic analysis, addressing a critical need for deep biological insights in research and diagnostics. This positions the company as a key player in advancing biotechnology tools that enhance accuracy and efficiency in life sciences.
Seer Inc.'s negative ROE of -25.7% indicates poor profitability and financial strain, as the company is not generating returns on shareholder equity and may be relying on external funding. Despite this, the 2.2% revenue growth reflects modest market acceptance of its products, though it highlights the need for improved cost management to achieve sustainable financial health.
By 2026, Seer Inc.'s Proteograph technology could capture significant market share in the growing proteomics sector, driven by increasing demand for advanced biological research tools and a projected expansion in biotechnology applications. The company's 2.2% revenue growth suggests early traction that may accelerate with wider adoption, potentially leading to profitability improvements. Additionally, the Tradestie Score of 58.0 indicates moderate investment appeal, making it a viable option for investors betting on long-term innovation in lab instruments.
BRKRP
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Bruker Corp is a key innovator in the Lab Instruments sector, providing essential scientific instruments and diagnostic tests that advance research in life sciences, pharmaceuticals, and biotechnology through specialized segments like BSI BioSpin and BSI Nano, which address critical needs in molecular analysis and nanotechnology.
With a Tradestie Score of 56.6/100 indicating moderate financial stability, Bruker demonstrates reliable performance in its core segments despite limited available data, supported by the 6.375% dividend yield on this preferred stock that ensures steady income amid operational consistency.
By 2026, Bruker's expansion in high-growth areas like biotechnology and nanotechnology is poised to drive revenue growth, fueled by increasing demand for advanced diagnostic tools in the pharmaceutical sector. The mandatory convertible feature of this preferred stock could convert to common shares at favorable terms if the company's stock appreciates, offering potential upside. Additionally, the fixed 6.375% yield provides a buffer against market volatility, making it an attractive option for income-focused investors anticipating sector recovery.
WAT
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. …
Waters Corp matters in the Lab Instruments sector as a leading provider of essential analytical tools like liquid chromatography and mass spectrometry, which are critical for drug discovery, environmental testing, and materials analysis, thereby driving innovations in healthcare and life sciences. Its specialized instruments enable precise molecular and physical property analysis, supporting industries that enhance global health and well-being.
Waters Corp exhibits strong profitability with a 20.9% profit margin, indicating efficient cost management and operational effectiveness, while its 33.0% ROE demonstrates superior returns on equity compared to industry peers. The 8.0% revenue growth further underscores financial health and expansion potential, though the 35.2 P/E ratio reflects a premium valuation that may require sustained growth to justify.
Waters Corp's 8.0% revenue growth positions it to benefit from increasing demand in pharmaceuticals and biotechnology by 2026, fueled by advancements in personalized medicine and regulatory requirements. The company's impressive 33.0% ROE highlights its ability to generate high returns, making it a compelling investment for long-term capital appreciation. Additionally, as global R&D investments rise, Waters' specialized instruments will likely see heightened adoption, supporting stock outperformance in the evolving lab instruments market.
BIO
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and …
Bio-Rad Laboratories matters in the Lab Instruments sector as a leading provider of specialized products for clinical diagnostics and life sciences, capturing 60% of its sales from essential test systems and quality controls that support global healthcare and research needs. Its established presence enables it to address critical demands in an industry driven by advancements in diagnostics and biotechnology.
Bio-Rad's negative profit margin of -26.4% reflects current operational losses, likely due to high R&D investments or market challenges, while a ROE of -9.5% indicates poor returns on shareholder equity, signaling financial strain. Despite this, the company's revenue growth of 0.5% shows modest top-line stability in a competitive sector.
By 2026, Bio-Rad could benefit from the projected growth in the clinical diagnostics market, driven by increasing demand for advanced testing solutions, potentially improving its revenue trajectory from the current 0.5% growth rate. The company's focus on innovative life sciences products may lead to enhanced profitability, offsetting the current -26.4% profit margin through market recovery and operational efficiencies. With a Tradestie Score of 56.3, the stock presents a moderate opportunity for investors seeking exposure to the expanding Lab Instruments sector.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.